Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era.

ABSTRACT:

Background

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and the most common type of non-Hodgkin lymphoma (NHL). The clinical use of rituximab has improved the treatment response and survival of patients with DLBCL. The introduction of rituximab biosimilar into healthcare system has helped in providing a cost-effective treatment to B-cell lymphoid malignancies as standard of care and has improved access to patients worldwide. The aim of this study was to observe the real-world effectiveness and safety of Reditux™ and Ristova^® in DLBCL patients.

Methods

Observational study in adults with DLBCL receiving Reditux™ or Ristova^® across 29 centers in India (2015-2022). Effectiveness and safety were assessed up to 2 years after first dose.

Results</

SUBMITTER: Nair R 

PROVIDER: S-EPMC10580068 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature